Placeholder Banner

BIO Comments to CMS on Oregon Proposed 1115 Waiver Application

April 1, 2022

The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the Oregon Health Authority’s (OHA) proposed Oregon Health Plan §1115 Demonstration Waiver Application (Waiver Application), which among other things, would be a waiver of compliance with essential provisions of §1927 of the Social Security Act (SSA) to exclude drugs approved through the FDA’s accelerated approval pathway (AAP). We urge CMS to reject those provisions of the proposed waiver that would exacerbate health disparities and jeopardize patient access and care, especially for patients with rare and chronic diseases.

Download Full Comments Below
BIO Comments to CMS on OHA Proposed 1115 Waiver Application
Discover More
On behalf of the Biotechnology Innovation Organization, I want to thank you for introducing the Patent Eligibility Restoration Act. This important legislation will bring much-needed and overdue clarity to Section 101 of the Patent Act. The existing…
The Council of State Bioscience Associations (CSBA) is an alliance of independent, state and territory based, non-profit trade associations, each of which advocates for public policies that support responsible development and delivery of innovative…
On Monday, June 13th, BIO submitted comments in response to a recently published FDA draft guidance providing recommendations to sponsors on developing a Race and Ethnicity Diversity Plan to enroll adequate numbers of participants in clinical trials…